Prevalence and disease burden of peripheral neuropathy in the general population in Mexico city: a cross-sectional epidemiological study

Figures & data

Table 1. Demographic information (all subjects).

Parameter	Subjects with PN (N = 448)	Subjects without PN (N = 2618)
Gender, n (%)
Female	268 (59.8)	1416 (54.1)
Male	180 (40.2)	1202 (45.9)
Age [years]
Mean (SD)	54.3 (7.74)	52.2 (7.95)
Q25%	48	45
Median	55	52
Q75%	61	60
Range	40–65	40–65
BMI [kg/m^2]
Mean (SD)	27.5 (4.69)	27.3 (4.63)
Q25%	24.2	24.1
Median	27.0	26.6
Q75%	30.2	29.8
Range	16.0–43.2	12.7–46.6

Abbreviations. BMI, body mass index; PN, peripheral neuropathy; Q, quartile; SD, standard deviation.

Table 2. Prevalence of PN based on MNSI results (all subjects).

PN prevalence category	N	Prevalence estimate (%)	95% CI
By definition
Site-defined: MNSI physical exam ≥2.5	3066	14.6	13.4;15.9
Sensitivity: MNSI physical exam ≥2.5 AND MNSI patient questionnaire ≥4	3066	12.7	11.6; 14.0
By gender
Male	1382	13.0	11.3;14.9
Female	1684	15.9	14.2;17.8
By age category [years]
40–45	731	10.1	8.0;12.5
46–50	611	12.8	10.2;15.7
51–55	561	15.0	12.1;18.2
56–60	485	17.3	14.1;21.0
61–65	678	18.9	16.0;22.0
By BMI category [kg/m^2]
Normal (18.5–<25)	1026	13.9	11.9;16.2
Overweight (25–<30)	1263	14.1	12.2;16.1
Obese (≥30)	737	16.0	13.4;18.9

Abbreviations. BMI, body mass index; CI, confidence interval; MNSI, Michigan Neuropathy Screening Instrument; PN, peripheral neuropathy.

Figure 1. Venn diagram of NTSS-6 most reported symptoms (numbness and prickling). Three of the 448 PN subjects had missing responses for NTSS-6. NTSS-6, Neuropathy Total Symptom Score-6; PN, peripheral neuropathy. Numbers in and next to circles are absolute numbers (n).

Figure 2. Intensity and frequency of NTSS-6 items in subjects with PN. Three subjects had missing responses for NTSS-6. NTSS-6, Neuropathy Total Symptom Score-6; PN, peripheral neuropathy.

Figure 3. HCP who diagnosed PN. HCP, healthcare professional; PN, peripheral neuropathy. Data extracted from Quality of Life Pharmacoeconomic Questionnaire.

Table 3. Information regarding PN diagnosis (subjects with PN only).

Duration with symptoms before being diagnosed [years]	N = 141
Mean (SD)	2.3 (3.07)
Q25%	0.4
Median	1
Q75%	3
Range	0.1–15.0
Visited doctor more than once before being diagnosed; n (%)	N = 358
Yes	89 (24.9)
No	269 (75.1)
Saw specialist after being diagnosed; n (%)	N = 448
Yes	70 (15.6)
No	378 (84.4)
Rated discomfort prior to diagnosis of PN (1 = minimal, 5 = strongest), n (%)	N = 379
1	89 (24.1)
2	77 (20.8)
3	93 (25.1)
4	63 (17.0)
5	48 (13.0)
Rated discomfort after diagnosis of PN (1 = minimal, 5 = strongest), n (%)	N = 364
1	94 (25.8)
2	86 (23.6)
3	91 (25.0)
4	48 (13.2)
5	45 (12.4)

Abbreviations. PN, peripheral neuropathy; Q, quartile; SD, standard deviation. Data extracted from Quality of Life Pharmacoeconomic Questionnaire.

Table 4. Prescribed treatment and supplements taken in addition (subjects with PN only).

Treatment prescribed by doctor after PN diagnosis; n (%)	N = 196 responses
Anticonvulsants	57 (29.0)
B vitamins	46 (23.5)
Non-opioid analgesics	39 (20.0)
None	15 (7.7)
Supplements taken in addition to prescribed medicine; n (%)	N = 356 responses
None	340 (95.5)
Homeopathic medicine	3 (0.8)
Folic acid and B vitamin complex	2 (0.6)
Garlic	2 (0.6)
Milk thistle	2 (0.6)
Moranguilla	2 (0.6)
Moringa	2 (0.6)
Herbal supplements	1 (0.3)
Chamomile tea	1 (0.3)
Valerian	1 (0.3)

Abbreviations. PN, peripheral neuropathy. Data extracted from Quality of Life Pharmacoeconomic Questionnaire. In individual cases, subjects may have responded with more than one option.